Heligenics

Executive Summary

Heligenics is a San Diego-based biotechnology company pioneering the functional analysis of all mutations in a single gene simultaneously. Founded in 2015, the company aims to improve human health by developing advanced diagnostics and better biologic drugs through high-content screening of genetic variants. By applying techniques historically used for small-molecule drugs to biologics such as insulin, GLP-1 agonists, and antibody therapies, Heligenics modernizes drug discovery and enables a deeper understanding of genetic variation's impact on disease. Despite its innovative approach, the company remains in a private stage with no disclosed funding, valuation, or commercial products, suggesting early development. Heligenics' platform holds potential for both therapeutic and diagnostic applications, but its lack of publicly available pipeline or partnerships limits visibility into near-term milestones. The company operates in the competitive genetics and genomics space, where functional genomics and precision medicine are rapidly evolving.

Upcoming Catalysts (preview)

• TBDSeries A or B Funding Round Announcement50% success
• TBDPartnership with a Major Pharma or Biotech for Drug Discovery30% success
• Q3 2026Publication of Proof-of-Concept Data in a Peer-Reviewed Journal70% success